Perceived benefits, information, vaccination history, and conspiracy beliefs as significant determinants of RSV vaccine acceptance among Arab seniors.

Malik Sallam, Kholoud Al-Mahzoum, Zainab Mansour Yousef, Jeelan Saleh Alfouzan, Maryam Jamal Alharbi, Mohammad Khaled Alsubaiei, Mohammed Yahya M Albalwah, Mohammad W Shehadeh, Rawan J Obeidat, Khaled O Yaseen, Doaa H Abdelaziz, Nesreen A Salim, Mohammed Sallam, Muna Barakat
Author Information
  1. Malik Sallam: Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan. ORCID
  2. Kholoud Al-Mahzoum: Sheikh Jaber Al-Ahmad Al-Sabah Hospital, Ministry of Health, Kuwait City, Kuwait.
  3. Zainab Mansour Yousef: School of Medicine, The University of Jordan, Amman, Jordan.
  4. Jeelan Saleh Alfouzan: School of Medicine, The University of Jordan, Amman, Jordan.
  5. Maryam Jamal Alharbi: School of Medicine, The University of Jordan, Amman, Jordan.
  6. Mohammad Khaled Alsubaiei: School of Medicine, The University of Jordan, Amman, Jordan.
  7. Mohammed Yahya M Albalwah: Istishari Hospital, Amman, Jordan.
  8. Mohammad W Shehadeh: Jordan University Hospital, Amman, Jordan.
  9. Rawan J Obeidat: The Office of Infection Prevention and Control, Jordan University Hospital, Amman, Jordan.
  10. Khaled O Yaseen: Faculty of Pharmacy, Mansoura University, El Mansoura, Egypt.
  11. Doaa H Abdelaziz: Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Baha University, Al-Baha, Saudi Arabia.
  12. Nesreen A Salim: Restorative Department, Faculty of Dentistry, Zarqa University, Zarqa, Jordan.
  13. Mohammed Sallam: Department of Pharmacy, Mediclinic Parkview Hospital, Mediclinic Middle East, Dubai, United Arab Emirates.
  14. Muna Barakat: Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.

Abstract

Background: Respiratory syncytial virus (RSV) poses a significant respiratory health risk to senior citizens, contributing substantially to hospitalizations and mortality. With the recent approval of three RSV vaccines for the elderly, it is critical to understand the factors that can shape the RSV vaccination attitudes to inform public health strategies that can enhance uptake among this vulnerable population.
Objectives: This study aimed to investigate the potential factors that could influence the attitudes toward RSV vaccination among senior citizens in Arab countries.
Design: A multinational cross-sectional study, adhering to STROBE guidelines, was conducted using a survey instrument previously validated through exploratory factor analysis to assess attitudes toward the newly approved RSV vaccine.
Methods: A self-administered online survey was distributed conveniently among senior citizens mainly across five Arab countries. The survey collected data on demographics, vaccination history, and key constructs related to RSV vaccine attitude, including "Fear," "Information," "Accessibility," "Benefits," and "Conspiracy."
Results: A total of 483 participants were included in the study, with the majority from five Arab countries: Jordan ( = 239, 49.5%), Kuwait ( = 74, 15.3%), Egypt ( = 68, 14.1%), Saudi Arabia ( = 51, 10.6%), and the UAE ( = 23, 4.8%), alongside participants from other Arab nations ( = 28, 5.8%). Among the respondents, 51.1% ( = 247) expressed acceptance of the RSV vaccine, 22.4% ( = 108) were hesitant, and 26.5% ( = 128) exhibited refusal. Multivariate analysis identified perceived benefits (β = 0.484,  < 0.001), information needs (β = 0.229,  < 0.001), and previous vaccination history (β = 0.087,  = 0.016) as significant positive predictors of vaccine acceptance. Conversely, stronger conspiracy beliefs (β = -0.083,  = 0.035) were associated with vaccine resistance. Fear and accessibility were not significant predictors of vaccine attitudes.
Conclusion: The findings showed that perceived benefits, access to reliable information, previous vaccination history, and conspiracy beliefs are essential to promote RSV vaccine acceptance among Arab seniors. These factors are recommended to improve RSV vaccine uptake in this vulnerable population.

Keywords

References

  1. Hum Vaccin Immunother. 2023 Dec 31;19(1):2194772 [PMID: 37005342]
  2. J Infect. 2008 Jun;56(6):460-8 [PMID: 18442855]
  3. J Health Soc Policy. 2003;18(2):71-93 [PMID: 15189797]
  4. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744 [PMID: 38253338]
  5. Vaccine. 2021 Jun 29;39(29):3803-3813 [PMID: 34099329]
  6. Int J Environ Res Public Health. 2020 Nov 22;17(22): [PMID: 33266386]
  7. Public Health Pract (Oxf). 2023 Jun;5:100349 [PMID: 36532098]
  8. Vaccines (Basel). 2023 Jan 13;11(1): [PMID: 36680024]
  9. Influenza Other Respir Viruses. 2024 Feb 03;18(2):e13236 [PMID: 38314063]
  10. Front Public Health. 2020 Nov 02;8:581836 [PMID: 33224920]
  11. Sci Rep. 2022 Aug 11;12(1):13681 [PMID: 35953500]
  12. J Adv Nurs. 2014 Sep;70(9):1970-1979 [PMID: 24684713]
  13. Vaccines (Basel). 2021 Nov 25;9(12): [PMID: 34960138]
  14. N Engl J Med. 2023 Dec 14;389(24):2233-2244 [PMID: 38091530]
  15. J Multidiscip Healthc. 2022 Jan 11;15:21-45 [PMID: 35046661]
  16. NPJ Vaccines. 2024 Apr 10;9(1):77 [PMID: 38600250]
  17. N Engl J Med. 2023 Feb 16;388(7):609-620 [PMID: 36791161]
  18. Health Commun. 2009 Jun;24(4):316-26 [PMID: 19499425]
  19. Infect Dis Rep. 2024 Mar 29;16(2):317-355 [PMID: 38667752]
  20. BMC Health Serv Res. 2023 May 2;23(1):423 [PMID: 37131261]
  21. PLoS Med. 2007 Oct 16;4(10):e296 [PMID: 17941714]
  22. Immun Inflamm Dis. 2024 Apr;12(4):e1257 [PMID: 38661110]
  23. Adv Ther. 2024 Nov;41(11):4312-4334 [PMID: 39312107]
  24. Vaccines (Basel). 2023 Jun 25;11(7): [PMID: 37514966]
  25. MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122 [PMID: 37824423]
  26. Lancet. 2022 May 28;399(10340):2047-2064 [PMID: 35598608]
  27. Nat Med. 2023 Mar;29(3):623-631 [PMID: 36720270]
  28. Public Health. 2018 Mar;156:67-78 [PMID: 29408191]
  29. Front Public Health. 2022 Dec 15;10:986916 [PMID: 36589991]
  30. Hum Vaccin Immunother. 2013 Aug;9(8):1795-801 [PMID: 23811786]
  31. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702 [PMID: 39146277]
  32. J Infect Dis. 2022 Aug 12;226(Suppl 1):S17-S21 [PMID: 34522961]
  33. Drugs Aging. 2024 Jun;41(6):487-505 [PMID: 38713299]
  34. Open Forum Infect Dis. 2023 Oct 20;10(11):ofad513 [PMID: 38033988]
  35. Hum Vaccin Immunother. 2023 Dec 15;19(3):2275962 [PMID: 37941437]
  36. Vaccine. 2022 Aug 5;40(33):4806-4815 [PMID: 35788295]
  37. Vaccine. 2024 May 10;42(13):3197-3205 [PMID: 38631951]
  38. Vaccines (Basel). 2024 May 05;12(5): [PMID: 38793751]
  39. Int J Environ Res Public Health. 2023 Feb 07;20(4): [PMID: 36833595]
  40. Hum Vaccin Immunother. 2024 Dec 31;20(1):2382502 [PMID: 39081126]
  41. Lancet. 2024 Mar 30;403(10433):1241-1253 [PMID: 38367641]
  42. Hum Vaccin Immunother. 2024 Dec 31;20(1):2388943 [PMID: 39161095]
  43. Vaccines (Basel). 2022 Aug 19;10(8): [PMID: 36016243]
  44. Vaccines (Basel). 2023 Aug 19;11(8): [PMID: 37631954]
  45. Nurs Open. 2023 Oct;10(10):6989-7002 [PMID: 37485792]
  46. Vaccine. 2015 Aug 14;33(34):4161-4 [PMID: 25896383]
  47. N Engl J Med. 2022 Jul 7;387(1):58-65 [PMID: 35767527]
  48. Appl Psychol Health Well Being. 2021 May;13(2):469-484 [PMID: 33634930]
  49. Eur Respir Rev. 2022 Nov 15;31(166): [PMID: 36384703]
  50. Infect Chemother. 2024 Mar;56(1):1-12 [PMID: 38527779]
  51. J Pediatr. 2016 Aug;175:248-249.e1 [PMID: 27507319]
  52. Vaccines (Basel). 2021 Feb 16;9(2): [PMID: 33669441]
  53. PLoS One. 2020 Dec 3;15(12):e0243264 [PMID: 33270783]
  54. Lancet. 2022 Sep 3;400(10354):729-730 [PMID: 36058217]
  55. Infect Dis Ther. 2025 Jan;14(Suppl 1):99-114 [PMID: 39739197]
  56. JAMA. 2013 Nov 27;310(20):2191-4 [PMID: 24141714]
  57. PLoS Med. 2021 Nov 4;18(11):e1003826 [PMID: 34735440]
  58. Vaccines (Basel). 2021 Jan 12;9(1): [PMID: 33445581]
  59. Pathophysiology. 2023 Apr 22;30(2):155-173 [PMID: 37218912]
  60. J Clin Epidemiol. 2008 Apr;61(4):344-9 [PMID: 18313558]
  61. JAMA. 2024 Aug 20;332(7):524 [PMID: 39058518]
  62. Soc Sci Med. 2022 May;301:114912 [PMID: 35354105]
  63. Pulm Ther. 2024 Mar;10(1):1-20 [PMID: 38358618]
  64. Front Pediatr. 2022 Nov 09;10:1033125 [PMID: 36440349]
  65. Front Public Health. 2018 Jun 11;6:149 [PMID: 29942800]
  66. Vaccines (Basel). 2023 Apr 25;11(5): [PMID: 37243001]
  67. Microorganisms. 2020 May 11;8(5): [PMID: 32403364]
  68. Vaccines (Basel). 2022 Jul 13;10(7): [PMID: 35891283]
  69. Curr Opin Psychol. 2022 Oct;47:101363 [PMID: 35732091]
  70. Korean J Anesthesiol. 2019 Dec;72(6):558-569 [PMID: 31304696]
  71. JNMA J Nepal Med Assoc. 2024 May 31;62(274):372-377 [PMID: 39356854]
  72. Med Lett Drugs Ther. 2024 Jul 22;66(1707):113-114 [PMID: 39008103]
  73. J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583 [PMID: 30880339]
  74. Prev Med Rep. 2024 Jun 07;43:102791 [PMID: 38947232]
  75. Curr Opin Infect Dis. 2024 Apr 1;37(2):129-136 [PMID: 38197402]
  76. Vaccine X. 2023 Nov 08;15:100405 [PMID: 38161986]
  77. J Pharm Policy Pract. 2023 Jun 13;16(1):72 [PMID: 37312223]
  78. Nat Hum Behav. 2022 Dec;6(12):1609-1610 [PMID: 36418535]
  79. N Engl J Med. 2023 Feb 16;388(7):595-608 [PMID: 36791160]
  80. Health Sci Rep. 2025 Jan 07;8(1):e70319 [PMID: 39777284]
  81. Infect Dis Rep. 2024 Aug 15;16(4):750-762 [PMID: 39195008]

Word Cloud

Created with Highcharts 10.0.0RSVvaccinevaccinationArabamongsignificanthealthattitudeshistory"acceptanceseniorcitizensfactorsstudysurveybenefitsβ = 0informationconspiracybeliefscanuptakevulnerablepopulationtowardcountriesanalysisfiveparticipants5%1%8%perceived< 0001previous = 0predictorsseniorsBackground:RespiratorysyncytialvirusposesrespiratoryriskcontributingsubstantiallyhospitalizationsmortalityrecentapprovalthreevaccineselderlycriticalunderstandshapeinformpublicstrategiesenhanceObjectives:aimedinvestigatepotentialinfluenceDesign:multinationalcross-sectionaladheringSTROBEguidelinesconductedusinginstrumentpreviouslyvalidatedexploratoryfactorassessnewlyapprovedMethods:self-administeredonlinedistributedconvenientlymainlyacrosscollecteddatademographicskeyconstructsrelatedattitudeincluding"Fear"Information"Accessibility"Benefits"Conspiracy"Results:total483includedmajoritycountries:Jordan = 23949Kuwait = 74153%Egypt = 6814SaudiArabia = 51106%UAE = 234alongsidenations = 285Amongrespondents51 = 247expressed224% = 108hesitant26 = 128exhibitedrefusalMultivariateidentified484needs229087016positiveConverselystrongerβ = -0083035associatedresistanceFearaccessibilityConclusion:findingsshowedaccessreliableessentialpromoterecommendedimprovePerceiveddeterminantsgeriatriccommunicationimmunizationhesitancy

Similar Articles

Cited By